BLOCKSYNOP INC

From the company

BLOCKsynop is developing the Neural Blockade Monitor (NBM), described as the first clinical monitoring device that provides an objective measurement to quantify controlled delivery and effectiveness of neural blocks on pain. The company states a prototype monitor for local anesthetics has been successfully designed and validated, providing a non-invasive, real-time tool for the anesthesiologist, and is being developed into a clinical product. The device is investigational and not approved for sale in the United States.